Valcyte · DIN 02306085 · 50 mg/mL · Pd for Oral Sol-100mL Pk
Limited Use, Reason for Use code 571, 572, 573 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 571, 572, 573 required
Write on scriptone applicable Reason for Use code, 571 or 572 or 573 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria, code 571, 572, 573
Reason for Use code 571
For those unable to swallow or tolerate solid oral dosage form AND
For the treatment of Cytomegalovirus (CMV) retinitis in patients with HIV/AIDS.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 572
For those unable to swallow or tolerate solid oral dosage form AND
For the prevention of Cytomegalovirus (CMV) in solid organ transplant patients (not lung or heart-lung).
Coverage limit:
LU Authorization Period: Up to 6 months
Reason for Use code 573
For those unable to swallow or tolerate solid oral dosage form AND
For the prevention of Cytomegalovirus (CMV) in lung or heart-lung transplant patients.
Coverage limit:
LU Authorization Period: Up to 12 months
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Valganciclovir
Brand(s): Valcyte and Generics
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50mg/mL pd for oral solution
For the treatment of moderate to severe symptomatic congenital CMV (cCMV) in newborns
who meet the following criteria:
• Prescribed by or in consultation with a pediatric ID specialist (from one of the 5
treatment centres in Ontario: London, Hamilton, Toronto, Kingston, Ottawa; or
Winnipeg for the North Western region of Ontario1)
• Confirmed diagnosis of cCMV within the first 3 weeks of birth by:
o PCR (urine, saliva or quantitative serum CMV); OR
o Positive culture results (urine or saliva)
• Treatment to start within one month of birth
• Evidence of one or more of the following symptoms:
o CNS disease (e.g., seizures, microcephaly, imaging abnormalities associated
with CMV)
o Eye disease (e.g., chorioretinitis)
o Severe life-threatening organ dysfunction (specify/describe)
• Regular monitoring of labs for toxicity while on therapy
51
Valganciclovir
Brand(s): Valcyte and Generics
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50 mg/mL pd for oral solutions
Approval Duration: maximum 6 months at 16mg/kg/dose BID (with dose adjustments in
renal dysfunction, < 32 weeks gestational age, etc.)
Renewals: No extensions will be provided unless extenuating circumstances for severely
affected infants. Case-by-case review with rationale for continued treatment (must include
pediatric ID specialist consult note)
All other requests not meeting the above criteria will be reviewed on a case-by-case basis
including:
• Initiation of treatment after one month of age
• Evidence of sensorineural hearing loss (SNHL) only (i.e., no other symptom
described above)
• Isolated/multiple findings of mild symptoms such as: intrauterine growth retardation
(IUGR), thrombocytopenia, elevated liver enzymes, jaundice, hepatitis
1List of treatment centres and addresses:
• Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa ON K1H 8L1
• Kingston General Hospital, 76 Stuart Street, Kingston ON K7L 2V7
• The Hospital for Sick Children, 555 University Avenue, Toronto ON M5G 1X8
• McMaster Children’s Hospital, 1200 Main Street West, Hamilton ON L8N 3Z5
• London Health Sciences Center, 339 Windermere Road, London ON N6A 5A5
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 51, record 29, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Valganciclovir
Brand(s): Valcyte
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50 mg/mL oral solution
For the treatment of cytomegalovirus (CMV) disease following solid organ and/or bone
marrow transplant in patients who meet the following criteria:
1. Objective evidence of active CMV infection determined by any one of the following
methods:
• CMV antigenemia assay;OR
• CMV polymerase chain reaction (PCR); OR
• bDNA assay; OR
• Tissue biopsy with pathological changes showing intra-nuclear inclusion bodies
compatible with CMV infection (i.e. Owl’s eye)
• Primary Infection - positive CMV IgM antibodies; OR
• Reactivation - Positive CMV IgM antibodies with four-fold or greater increase in
CMV IgG antibodies
2. Consolidation phase of treatment (maintenance phase post-induction with IV
ganciclovir)
Standard Approval Duration: 3 to 6 months
Renewals will be considered for patients who continue to have active CMV infection.
Renewal requests not meeting the criteria will be considered on a case-by-case basis but
the physician must submit a rationale of why ongoing treatment is necessary.
Standard Approval Duration: 3 months
For prophylaxis (prevention) of Epstein-Barr Virus (EBV) infection in EBV D+/R-
transplant recipients.
Standard Approval Duration: 6 months
476
Valganciclovir
Brand(s): Valcyte
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50 mg/mL oral solution
For treatment of Epstein-Barr Virus (EBV) infection in transplant patients according to
the following criteria:
1. Confirmed via biopsy (rare EBV positive cells present); OR
2. Objective evidence of active EBV infection (Patient must have one of the three below):
• Newly positive or rising EBV PCR; OR
• Reactivation: Positive anti-VCA IgM antibodies with a four-fold or greater increase
in anti-VCA IgG antibodies; OR
• Presence of EBV DNA or protein in pathologic tissue
Standard Approval Duration: 3 months
Notes:
Valganciclovir oral solution is considered for patients who meet the above requirements
but who cannot swallow tablets or cannot use the tablets to achieve the planned dosing
regimen.
Renewals for patients showing continued active infection with EBV PCR may be
considered on a case-by-case basis by submitting the request to the EAP.
Requests for valganciclovir not meeting the above criteria or the Limited Use criteria on the
formulary will be considered on a case-by-case basis but the prescriber must submit the
request to the EAP.
477
Valganciclovir
Brand(s): Valcyte
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50 mg/mL oral solution
Approvals will be provided for the treatment of moderate to severe symptomatic
congenital CMV (cCMV) in newborns who meet the following criteria:
• Prescribed by or in consultation with a pediatric ID specialist (from one of the 5
treatment centres in Ontario: London, Hamilton, Toronto, Kingston, Ottawa; or
Winnipeg for the NorthWestern region of Ontario)
• Confirmed diagnosis of cCMV within the first 3 weeks¹ of birth by:
o PCR (urine, saliva or quantitative serum CMV); OR
o Positive culture results (urine or saliva)
• Treatment to start within one month of birth²
• Evidence of one or more of the following symptoms:
o CNS disease (e.g., seizures, microcephaly, imaging abnormalities associated
with CMV)
o Eye disease (e.g., chorioretinitis)
o Severe life-threatening organ dysfunction (must be described)³
• Regular monitoring of labs for toxicity while on therapy
Approval Duration: maximum 6 months at 16mg/kg/dose BID (with dose adjustments in
renal dysfunction, < 32 weeks gestational age, etc.)
Renewals: No extensions will be provided unless extenuating circumstances for severely
affected infants. Case-by-case review with rationale for continued treatment (must include
pediatric ID specialist consult note)
Valganciclovir oral liquid will be approved for newborns.
All other requests not meeting the above criteria will be reviewed on a case-by-case basis
including:
• Initiation of treatment after one month of age²
• Evidence of sensorineural hearing loss (SNHL) only (i.e., no other symptom
described above)
• Isolated/multiple findings of mild symptoms such as: intrauterine growth retardation
(IUGR), thrombocytopenia, elevated liver enzymes, jaundice, hepatitis
Sufficient rationale including consult from pediatric ID specialist must be provided before
sending for external review.
478
Renewals of HIV Drugs
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 476, record 318, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days | (ontario.ca, Updated October 05, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated October 05, 2026 ↗)
Savings card: innoviCares lists Valcyte (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists Valcyte (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, September 10, 2026 ↗)
1 brand, same coverage
Valcyte · DIN 02306085
Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 2020-02-28
Health Canada: Marketed since 2022-07-19 · brand VALCYTE · ATC J05AB14 VALGANCICLOVIR · form Powder for solution · route Oral · ingredients VALGANCICLOVIR (VALGANCICLOVIR HYDROCHLORIDE) 50 MG/ML · company Cheplapharm arzneimittel gmbh · schedule Prescription
DIN 02306085: Valcyte
Raw flags: sec12=Y, sec3=Y
Item: 081800108; group id 115; item number 0198; lccId 00328; manufacturer id CHE
Source form: Pd for Oral Sol-100mL Pk; strength: 50mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $321.8454; ministry $150.9900
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02306085
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79164Interchangeable products
Auro-Valganciclovir · DIN 02535483 · $150.9900
Shortage status: not checked (no credentials)
Other products in the same Health Canada class (J05A, J05AB): coverage varies; not interchangeable
Acyclovir (Zovirax): general benefit, not a benefit
Ganciclovir (Cytovene): general benefit
Valacyclovir (Valtrex): general benefit, not a benefit
Famciclovir (Famvir): limited Use 147, not a benefit
Remdesivir (Veklury): limited Use 722
Abacavir + lamivudine + zidovudine (Trizivir): general benefit
48 more in the class list below
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered
Matched class: 08:18 Antivirals
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR
Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR
08:18 Antivirals
1 INDICATIONS
VALCYTE (valganciclovir hydrochloride, film coated tablets and powder for oral solution) is indicated for
adult patients for:
The treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency
syndrome (AIDS).
The prevention of cytomegalovirus (CMV) disease in solid organ transplant patients who are at risk.
This indication is based on a double‐blind, double‐dummy, active comparator study in heart, liver,
kidney and kidney‐pancreas transplant patients at high risk for CMV disease (donor CMV
seropositive/recipient seronegative [D+/R‐] (see 7 WARNINGS AND PRECAUTIONS and 14 CLINICAL
TRIALS for information on specific solid organ transplant subgroups)).
1.1 Pediatrics
Pediatrics (< 18 years of age): Safety and efficacy of VALCYTE in pediatric patients have not been
established; therefore, Health Canada has not authorized an indication for pediatric use (See 7
WARNINGS AND PRECAUTIONS , 7.1 Special Populations , 7.1.3 Pediatrics ).
1.2 Geriatrics
Geriatrics (> 65 years of age): The pharmacokinetic profiles of VALCYTE in elderly patients have not
been established. (See 7 WARNINGS AND PRECAUTI…
https://pdf.hres.ca/dpd_pm/00066612.PDF
PM date: July 11, 2022
Source product: VALCYTE; DIN 02245777; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year:
SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE
Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.
EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026
Posted turnaround and Telephone Request Service scope
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 28, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 1 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 1 business day |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 14 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Valganciclovir
Brand(s): Valcyte and Generics
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50mg/mL pd for oral solution
For the treatment of moderate to severe symptomatic congenital CMV (cCMV) in newborns
who meet the following criteria:
• Prescribed by or in consultation with a pediatric ID specialist (from one of the 5
treatment centres in Ontario: London, Hamilton, Toronto, Kingston, Ottawa; or
Winnipeg for the North Western region of Ontario1)
• Confirmed diagnosis of cCMV within the first 3 weeks of birth by:
o PCR (urine, saliva or quantitative serum CMV); OR
o Positive culture results (urine or saliva)
• Treatment to start within one month of birth
• Evidence of one or more of the following symptoms:
o CNS disease (e.g., seizures, microcephaly, imaging abnormalities associated
with CMV)
o Eye disease (e.g., chorioretinitis)
o Severe life-threatening organ dysfunction (specify/describe)
• Regular monitoring of labs for toxicity while on therapy
51
Valganciclovir
Brand(s): Valcyte and Generics
DOSAGE FORM/ STRENGTH: 450 mg tablet, 50 mg/mL pd for oral solutions
Approval Duration: maximum 6 months at 16mg/kg/dose BID (with dose adjustments in
renal dysfunction, < 32 weeks gestational age, etc.)
Renewals: No extensions will be provided unless extenuating circumstances for severely
affected infants. Case-by-case review with rationale for continued treatment (must include
pediatric ID specialist consult note)
All other requests not meeting the above criteria will be reviewed on a case-by-case basis
including:
• Initiation of treatment after one month of age
• Evidence of sensorineural hearing loss (SNHL) only (i.e., no other symptom
described above)
• Isolated/multiple findings of mild symptoms such as: intrauterine growth retardation
(IUGR), thrombocytopenia, elevated liver enzymes, jaundice, hepatitis
1List of treatment centres and addresses:
• Children’s Hospital of Eastern Ontario, 401 Smyth Road, Ottawa ON K1H 8L1
• Kingston General Hospital, 76 Stuart Street, Kingston ON K7L 2V7
• The Hospital for Sick Children, 555 University Avenue, Toronto ON M5G 1X8
• McMaster Children’s Hospital, 1200 Main Street West, Hamilton ON L8N 3Z5
• London Health Sciences Center, 339 Windermere Road, London ON N6A 5A5
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.
Valganciclovir (Valcyte)
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Prepare answers: For the treatment of cytomegalovirus (CMV) disease following solid organ and/or bone
marrow transplant in patients who meet the following criteria:
For the treatment of cytomegalovirus (CMV) disease following solid organ and/or bone
marrow transplant in patients who meet the following criteria:
1. Objective evidence of active CMV infection determined by any one of the following
methods:
• CMV antigenemia assay;OR
• CMV polymerase chain reaction (PCR); OR
• bDNA assay; OR
• Tissue biopsy with pathological changes showing intra-nuclear inclusion bodies
compatible with CMV infection (i.e. Owl’s eye)
• Primary Infection - positive CMV IgM antibodies; OR
• Reactivation - Positive CMV IgM antibodies with four-fold or greater increase in
CMV IgG antibodies
2. Consolidation phase of treatment (maintenance phase post-induction with IV
ganciclovir)
Standard Approval Duration: 3 to 6 months
Renewals will be considered for patients who continue to have active CMV infection.
Renewal requests not meeting the criteria will be considered on a case-by-case basis but
the physician must submit a rationale of why ongoing treatment is necessary.
Standard Approval Duration: 3 months
For prophylaxis (prevention) of Epstein-Barr Virus (EBV) infection in EBV D+/R-
transplant recipients.
For treatment of Epstein-Barr Virus (EBV) infection in transplant patients according to
the following criteria:
1. Confirmed via biopsy (rare EBV positive cells present); OR
2. Objective evidence of active EBV infection (Patient must have one of the three below):
• Newly positive or rising EBV PCR; OR
• Reactivation: Positive anti-VCA IgM antibodies with a four-fold or greater increase
in anti-VCA IgG antibodies; OR
• Presence of EBV DNA or protein in pathologic tissue
Standard Approval Duration: 3 months
Notes:
Valganciclovir oral solution is considered for patients who meet the above requirements
but who cannot swallow tablets or cannot use the tablets to achieve the planned dosing
regimen.
Renewals for patients showing continued active infection with EBV PCR may be
considered on a case-by-case basis by submitting the request to the EAP.
Requests for valganciclovir not meeting the above criteria or the Limited Use criteria on the
formulary will be considered on a case-by-case basis but the prescriber must submit the
request to the EAP.
Approvals will be provided for the treatment of moderate to severe symptomatic
congenital CMV (cCMV) in newborns who meet the following criteria:
• Prescribed by or in consultation with a pediatric ID specialist (from one of the 5
treatment centres in Ontario: London, Hamilton, Toronto, Kingston, Ottawa; or
Winnipeg for the NorthWestern region of Ontario)
• Confirmed diagnosis of cCMV within the first 3 weeks¹ of birth by:
o PCR (urine, saliva or quantitative serum CMV); OR
o Positive culture results (urine or saliva)
• Treatment to start within one month of birth²
• Evidence of one or more of the following symptoms:
o CNS disease (e.g., seizures, microcephaly, imaging abnormalities associated
with CMV)
o Eye disease (e.g., chorioretinitis)
o Severe life-threatening organ dysfunction (must be described)³
• Regular monitoring of labs for toxicity while on therapy
Approval Duration: maximum 6 months at 16mg/kg/dose BID (with dose adjustments in
renal dysfunction, < 32 weeks gestational age, etc.)
Renewals: No extensions will be provided unless extenuating circumstances for severely
affected infants. Case-by-case review with rationale for continued treatment (must include
pediatric ID specialist consult note)
Valganciclovir oral liquid will be approved for newborns.
All other requests not meeting the above criteria will be reviewed on a case-by-case basis
including:
• Initiation of treatment after one month of age²
• Evidence of sensorineural hearing loss (SNHL) only (i.e., no other symptom
described above)
• Isolated/multiple findings of mild symptoms such as: intrauterine growth retardation
(IUGR), thrombocytopenia, elevated liver enzymes, jaundice, hepatitis
Sufficient rationale including consult from pediatric ID specialist must be provided before
sending for external review.
478
Renewals of HIV Drugs
Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.